What is the CAPTAIN study?
The CAPTAIN study provides evidence to support tailoring of asthma treatment based on symptom and risk assessment…
Commonly Asked Questions
Using data from the CAPTAIN1 study, Professor Neil Barnes and Dr David Leather answer common questions about the role of LAMA as part of triple therapy in the treatment of asthma.
Is there a biomarker that predicts response to a LAMA in asthma?
Professor Neil Barnes discusses the importance of lung function as a clinical biomarker to predict response to LAMA in asthma.
Is there rationale for adding a LAMA to treat elderly patients with little or no airflow obstruction?
Dr David Leather discusses the use of LAMA in elderly patients who are short of breath but show little or no airflow obstruction upon testing.
How does the CAPTAIN study in asthma inform a Treatable Traits approach?
Professor Neil Barnes discusses the key takeaways from the CAPTAIN study and how it informs a treatable traits approach to asthma treatment.
Related materials
References
- Lee L, et al. Lancet Respir Med. 2021;9(1):69–84.
Asthma Forward is a registered trademark of the GSK group of companies.
©2023 GSK group of companies. All rights reserved.
NX-GBL-FVU-WCNT-230007 | Date of preparation: October 2023